IDO1 and triple-negative breast carcinoma: In conclusion, Schisandrin A exhibits potential anti-triple-negative breast cancer (TNBC) effects by modulating and regulating diverse pathways, including GSK3B and IDO1, alongside its impact on the cell cycle and immune microenvironment.